Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 11 of 891 for:    nicotinamide

Nicotinamide Riboside and Metabolic Health

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2016 by Maastricht University Medical Center
Dutch Heart Foundation
Information provided by (Responsible Party):
Maastricht University Medical Center Identifier:
First received: July 8, 2016
Last updated: July 13, 2016
Last verified: July 2016
This study will investigate the effects of 6 week Nicotinamide Riboside supplementation (1000 mg/day) on metabolic health in healthy (pre)obese humans. The primary objective will be hepatic and whole body insulin sensitivity. Secondary objectives, to provide information about the underlying mechanism, will be muscle mitochondrial function, brown fat activity, ectopic lipid accumulation, energy metabolism, cardiovascular risk parameters, body composition and acetylcarnitine levels.

Condition Intervention
Insulin Resistance
Dietary Supplement: Nicotinamide Riboside (Niagen)
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Nicotinamide Riboside on Metabolic Health in (Pre)Obese Humans

Resource links provided by NLM:

Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • Insulin sensitivity: muscle- and liver specific [ Time Frame: 6 weeks after supplementation ] [ Designated as safety issue: No ]
    Hyperinsulinemic euglycemic clamp: Rate of glucose disappearance (Rd) will be calculated by using tracer kinetics.

Secondary Outcome Measures:
  • Muscle mitochondrial function (ex vivo) [ Time Frame: 6 weeks after supplementation ] [ Designated as safety issue: No ]
    Ex vivo mitochondrial function in skeletal muscle measured by oxygen consumption in muscle fibres (muscle biopsy vastus lateralis) on lipid-derived and carbohydrate-derived substrates.

  • Ectopic lipid accumulation [ Time Frame: 6 weeks after supplementation ] [ Designated as safety issue: No ]
    Liver and skeletal muscle lipid accumulation measured with H-MRS in vivo.

  • Brown adipose tissue activity [ Time Frame: 6 weeks after supplementation ] [ Designated as safety issue: No ]
    Subjects will be exposed to an individualized cooling protocol, after which an 18F-FDG PET/CT scan is made

  • Cardiovascular risk parameters [ Time Frame: 6 weeks after supplementation ] [ Designated as safety issue: No ]
    Cardiac energy status measured with P-MRS.

  • Whole body energy expenditure [ Time Frame: 6 weeks after supplementation ] [ Designated as safety issue: No ]

    Sleeping metabolic rate measured during an overnight stay in a respiration chamber.

    Resting metabolic rate measured with ventilated hood system, basal, during insulin stimulation (clamp) and during cold stimulation (cooling protocol BAT activity).

  • Body composition [ Time Frame: 6 weeks after supplementation ] [ Designated as safety issue: No ]
    Fat mass and fat free mass measured with a BodPod.

  • Acetylcarnitine levels [ Time Frame: 6 weeks after supplementation ] [ Designated as safety issue: No ]
    Skeletal muscle acetylcarnitine levels measured with H-MRS in vivo, before and after exercise stimulation (cycling).

Estimated Enrollment: 15
Study Start Date: October 2016
Estimated Study Completion Date: April 2017
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nicotinamide Riboside
Supplementation of Nicotinamide Riboside (Niagen) of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
Dietary Supplement: Nicotinamide Riboside (Niagen) Dietary Supplement: Placebo
Placebo Comparator: Placebo
Supplementation of Placebo of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
Dietary Supplement: Nicotinamide Riboside (Niagen) Dietary Supplement: Placebo


Ages Eligible for Study:   45 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Signed informed consent
  • Caucasian
  • Males and postmenopausal females
  • Aged 45-65 years at start of the study
  • Body mass index (BMI) 27 - 35 kg/m2
  • Stable dietary habits (no weight loss or gain >5kg in the past 3 months)
  • Sedentary lifestyle (not more than 2 hours of sports per week)

Exclusion Criteria:

  • Type 2 diabetes
  • Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other)
  • Contra-indication for MRI
  • Participation in earlier research or medical examination that included PET/CT scanning
  • Alcohol consumption of >2 servings per day
  • Smoking in the past 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02835664

Contact: Carlijn Remie, Msc 0031 43 3884596
Contact: Patrick Schrauwen, PhD 0031 43 3881502

Sponsors and Collaborators
Maastricht University Medical Center
Dutch Heart Foundation
Principal Investigator: Patrick Schrauwen, PhD Maastricht University Medical Center
  More Information

Responsible Party: Maastricht University Medical Center Identifier: NCT02835664     History of Changes
Other Study ID Numbers: NL58119.068.16 
Study First Received: July 8, 2016
Last Updated: July 13, 2016
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Maastricht University Medical Center:
Nicotinamide Riboside
Metabolic health
Insulin resistance
Mitochondrial function
Brown adipose tissue
Energy expenditure
Ectopic lipid accumulation
Cardiovascular risk

Additional relevant MeSH terms:
Nicotinic Acids
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Vasodilator Agents processed this record on October 25, 2016